BioCentury
ARTICLE | Clinical News

BPX-01: Completed Ph II enrollment

January 5, 2017 9:58 PM UTC

BioPharmX completed enrollment of 225 patients with moderate to severe inflammatory, non-nodular acne vulgaris in the double-blind, placebo-controlled, U.S. Phase IIb OPAL trial evaluating about 1 g o...

BCIQ Company Profiles

Timber Pharmaceuticals LLC